Biologics Manufacturing Service

Hisun’s Biologics division has been in operation since 2003. Operating over the two manufacturing sites, our areas of expertise include monoclonal antibody, Recombinant protein and Fusion protein/peptide/cell factor/vaccine, antibody drug conjugation. Hisun was the first to develop and launch a bio-better version of Enbrel, in China, and we currently have several bio-similar products in late stage clinical development. Our highly skilled biologics team welcomes the opportunity to provide custom services and co-development of biosimilars for different countries. We apply our breadth of technologies, skilled workforce, and state-of-the-art facilities while leveraging a cost competitive base for the benefit or our clients and partners.

Biologics Manufacturing Capability

Monoclonal Antibody

  • Recombinant and Fusion Protein
  • Peptide
  • Cell Factor
  • Vaccine
  • Antibody Drug Conjugates

Protein Engineering

  • Cell Line development
  • Cloning
  • Protein expression

Biologics Manufacturing Capacity

  • Cell culture lines -- up to 2x300L, 2x2, 250L
  • Microbial lines -- 500L, 2x15,00L